

**POSTER PRESENTATION**

**Open Access**

# Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

Kyle K Payne<sup>1\*</sup>, Christine K Zoon<sup>1</sup>, Wen Wan<sup>1</sup>, Khin Marlar<sup>2</sup>, Rebecca C Keim<sup>1</sup>, Mehrab Nasiri Kenari<sup>2</sup>, Latif Kazim<sup>2</sup>, Harry D Bear<sup>1</sup>, Masoud H Manjili<sup>1</sup>

From Society for Immunotherapy of Cancer 28th Annual Meeting  
National Harbor, MD, USA. 8-10 November 2013

Barriers limiting the efficacy of adoptive cellular therapy (ACT) for breast cancer patients include immune suppression mediated by myeloid-derived suppressor cells (MDSC) and a low frequency of tumor-reactive memory T cells (T<sub>m</sub>). Recently, we developed an ex vivo protocol to reprogram tumor-reactive murine splenocytes; these cells were found to be resistant to MDSC suppression and protected FVBN202 mice from tumor challenge. Here, we evaluated the clinical applicability of reprogramming tumor-sensitized PBMCs isolated from patients with early stage breast cancer by treatment with bryostatin 1 and ionomycin (B/I) combined with IL-2, IL-7 and IL-15. Our data demonstrate that reprogrammed cells are enriched with T<sub>m</sub> cells (n=5; p=0.006), as well as activated CD56<sup>+</sup> (n=6; p=0.003) and CD161<sup>+</sup> (n=4; p=0.02) NKT cells, and demonstrate expansion in total cell numbers (n=16; p=0.003) compared to baseline cells. Reprogrammed PBMCs displayed enhanced HER-2/neu-specific IFN- $\gamma$  producing immune responses (n=6; p=0.04); non-reprogrammed control PBMC IFN- $\gamma$  production was not significant (n=6; p=0.4). Furthermore, high-throughput sequencing analysis of the T cell receptor (TcR) V $\beta$  in one patient demonstrated clonal expansion of specific TcR VJ recombination events resulting from cellular reprogramming, suggestive of an

enriched frequency of specific tumor antigen-primed T cell clones. Interestingly, reprogrammed T cells were resistant to autologous CD33<sup>+</sup> CD11b<sup>+</sup> HLA-DR<sup>lo/-</sup> MDSCs, as determined by further enhanced HER-2/neu-specific IFN- $\gamma$  secretion in the presence of MDSCs (n=6; p=0.03). Activated CD161<sup>+</sup> NKT cells comprising 3% or greater of total reprogrammed cells rendered T cells resistant to MDSCs (n=3; p=0.02). Upregulation of NKG2D expression on CD161<sup>+</sup> (n=5; p=0.0006) and CD56<sup>+</sup> (n=5; p=0.04) NKT cells resulted from cellular reprogramming. Therefore, NKG2D signaling was blocked using anti-NKG2D blocking antibody in our co-culture system, resulting in the abrogation of resistance to MDSCs as determined by blunted IFN- $\gamma$  secretion (n=3; p=0.04). Finally, the phenotype of MDSCs after co-culture with reprogrammed PBMC was examined; we observed down-regulation of CD11b expression (n=3; p=0.02) concomitant with HLA-DR upregulation on MDSCs (n=3; p=0.001); suggestive of induced maturation of MDSCs into Dendritic Cells (DC). The results of our study offer the following strategies to improve ACT of breast cancer: i) inclusion of activated NKT cells in ACT to overcome MDSC suppression by inducing MDSC maturation into DCs, and ii) PBMC reprogramming to enrich the frequency of tumor-reactive T<sub>m</sub> cells.

<sup>1</sup>Virginia Commonwealth University - Massey Cancer Center, Richmond, VA, USA

Full list of author information is available at the end of the article

**Authors' details**

<sup>1</sup>Virginia Commonwealth University - Massey Cancer Center, Richmond, VA, USA. <sup>2</sup>Roswell Park Cancer Institute, Buffalo, NY, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P170

**Cite this article as:** Payne *et al.*: Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. *Journal for ImmunoTherapy of Cancer* 2013 1(Suppl 1):P170.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

